Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 1
1983 5
1984 8
1985 10
1986 42
1987 18
1988 24
1989 20
1990 20
1991 31
1992 24
1993 28
1994 32
1995 30
1996 35
1997 33
1998 32
1999 26
2000 28
2001 21
2002 30
2003 29
2004 26
2005 36
2006 22
2007 19
2008 22
2009 26
2010 39
2011 37
2012 35
2013 44
2014 35
2015 40
2016 29
2017 45
2018 57
2019 56
2020 63
2021 61
2022 66
2023 52
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,282 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for g imipenem
Your search for grimipinem retrieved no results
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Kaye KS, et al. Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.
All patients received imipenem-cilastatin (1.0 g of each drug in combination over 1 h every 6 h) as background therapy. ...INTERPRETATION: Our data show that sulbactam-durlobactam was non-inferior to colistin, both agents given in combination with imipenem-ci …
All patients received imipenem-cilastatin (1.0 g of each drug in combination over 1 h every 6 h) as background therapy. ...INT …
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. Titov I, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803. Clin Infect Dis. 2021. PMID: 32785589 Free PMC article. Clinical Trial.
We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). METHODS: This was a randomized, controlled, double-blind phase 3 trial. Adults with HABP/VABP were randomized 1:1 to i …
We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating hospital-acquired/ventilator-associated bacterial pneu …
Imipenem.
Hellinger WC, Brewer NS. Hellinger WC, et al. Mayo Clin Proc. 1991 Oct;66(10):1074-81. doi: 10.1016/s0025-6196(12)61732-7. Mayo Clin Proc. 1991. PMID: 1921491 Review.
Imipenem is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. ...Like the penicillins, imipenem has inhibitory activity against enterococci. Daily doses may range from 500 mg to 1 g, every 6 to 8 hours, in …
Imipenem is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. ...Like the penici …
Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
Fratoni AJ, Mah JW, Nicolau DP, Kuti JL. Fratoni AJ, et al. J Antimicrob Chemother. 2022 Oct 28;77(11):2992-2999. doi: 10.1093/jac/dkac261. J Antimicrob Chemother. 2022. PMID: 35906810
Augmented renal clearance (ARC) is a common syndrome in critically-ill patients with sepsis, and sub-therapeutic antibiotic concentrations are of concern. Herein, we describe the pharmacokinetics of imipenem/relebactam in critically-ill patients with ARC. METHODS: Infected …
Augmented renal clearance (ARC) is a common syndrome in critically-ill patients with sepsis, and sub-therapeutic antibiotic concentrations a …
Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A, Meli EZ, Mazzocchi P, Speranza V. Basoli A, et al. Scand J Infect Dis. 1997;29(5):503-8. doi: 10.3109/00365549709011863. Scand J Infect Dis. 1997. PMID: 9435041 Clinical Trial.
An open-label prospective, randomized, parallel multicentre study was undertaken to compare the efficacy and tolerability of 1.5 g/day intravenous imipenem/cilastatin with 3 g/day intravenous meropenem in the treatment of intra-abdominal infections. ...This s …
An open-label prospective, randomized, parallel multicentre study was undertaken to compare the efficacy and tolerability of 1.5 g/da …
Carbapenems.
Norrby SR. Norrby SR. Med Clin North Am. 1995 Jul;79(4):745-59. doi: 10.1016/s0025-7125(16)30037-2. Med Clin North Am. 1995. PMID: 7791421 Review.
The risk for neurologic reactions with imipenem-cilastatin has become a factor reducing the possibilities to use high doses. For all indications except bacterial meningitis, the now approved maximal dose of 4 g per day should suffice. In this respect, meropenem has …
The risk for neurologic reactions with imipenem-cilastatin has become a factor reducing the possibilities to use high doses. For all …
Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
Pastel DA. Pastel DA. Clin Pharm. 1986 Sep;5(9):719-36. Clin Pharm. 1986. PMID: 3530614 Review.
For infections with multiple organisms (e.g., pelvic, intra-abdominal, or soft-tissue infections), imipenem-cilastatin may be a cost-effective and less toxic single-agent alternative to "standard" combination (e.g., aminoglycoside-penicillin plus an antianaer …
For infections with multiple organisms (e.g., pelvic, intra-abdominal, or soft-tissue infections), imipenem-cilastatin may be …
Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, Morel P, Lew D, Zimmerli W, Lange J, Glauser M. Zanetti G, et al. Int J Antimicrob Agents. 1999 Feb;11(2):107-13. doi: 10.1016/s0924-8579(98)00104-6. Int J Antimicrob Agents. 1999. PMID: 10221413 Clinical Trial.
This multicentre, open-label, randomised trial compared meropenem (0.5 g/8 h) and imipenem/cilastatin (at the commonly used dosage of 0.5 g/6 h) in monotherapy in patients with moderately severe intra-abdominal infections (IAIs). ...Both drugs were generally …
This multicentre, open-label, randomised trial compared meropenem (0.5 g/8 h) and imipenem/cilastatin (at the commonly used do …
Imipenem Resistance Mediated by bla(OXA-913) Gene in Pseudomonas aeruginosa.
Moon DC, Mechesso AF, Kang HY, Kim SJ, Choi JH, Song HJ, Yoon SS, Lim SK. Moon DC, et al. Antibiotics (Basel). 2021 Sep 29;10(10):1188. doi: 10.3390/antibiotics10101188. Antibiotics (Basel). 2021. PMID: 34680769 Free PMC article.
Nevertheless, we did not detect any of the previously reported carbapenem resistance genes. This is the first report of the bla(OXA-913) gene in imipenem-resistant P. aeruginosa in the literature. Notably, no viable colonies were found after co-treatment with imipenem …
Nevertheless, we did not detect any of the previously reported carbapenem resistance genes. This is the first report of the bla(OXA-913) gen …
Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
Hellinger WC, Brewer NS. Hellinger WC, et al. Mayo Clin Proc. 1999 Apr;74(4):420-34. doi: 10.4065/74.4.420. Mayo Clin Proc. 1999. PMID: 10221472 Review.
Imipenem and meropenem, members of the carbapenem class of beta-lactam antibiotics, are among the most broadly active antibiotics available for systemic use in humans. ...Daily dosages may range from 0.5 to 1 g every 6 to 8 hours in patients with normal renal functi …
Imipenem and meropenem, members of the carbapenem class of beta-lactam antibiotics, are among the most broadly active antibiotics ava …
1,282 results